Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.54 |
| ▸ | MLNR | O43193 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977827 | 0.94 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL1978836 | 0.94 | CYP3A4 (0.61) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL1977717 | 0.90 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL14655982 | 0.89 | CYP3A4 (0.48) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL1978154 | 0.89 | CYP3A4 (0.59) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL1977691 | 0.89 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL1980245 | 0.87 | CYP3A4 (0.58) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL1979331 | 0.87 | CYP3A4 (0.69) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL1981664 | 0.87 | CYP3A4 (0.60) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL1979206 | 0.85 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426388-B2 | Prodrugs of HIV protease inhibitors | ABBVIE INC. (US) | 2013-04-23 | — | — | US | claimed |
| EP-1773850-B1 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LAB (US) | 2013-01-30 | — | — | EP | claimed |
| US-20100286032-A1 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | claimed |
| US-7718633-B2 | Prodrugs of HIV protease inhibitors | ABBOTT LABORATORIES (US) | 2010-05-18 | — | — | US | claimed |
| US-20070270383-A1 | Prodrugs of HIV protease inhibitors | ABBVIE INC. | 2007-11-22 | — | — | US | claimed |
| US-8426388-B2 | Prodrugs of HIV protease inhibitors | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-1773850-B1 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LAB (US) | 2013-01-30 | — | — | EP | disclosed |
| EP-2336138-A2 | Prodrugs of HIV protease inhibitors | ABBOTT LABORATORIES (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100286032-A1 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | disclosed |
| US-7718633-B2 | Prodrugs of HIV protease inhibitors | ABBOTT LABORATORIES (US) | 2010-05-18 | — | — | US | disclosed |
| US-20070270383-A1 | Prodrugs of HIV protease inhibitors | ABBVIE INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286032-A1 | PRODRUGS OF HIV PROTEASE INHIBITORS | PREP, PEPD, SERPINB1 | CYP3A4 151/4885CYP2D6 265/4885CYP2C19 154/4885 |
| US-20070270383-A1 | Prodrugs of HIV protease inhibitors | PREP, PEPD, SERPINB1 | CYP3A4 151/4885CYP2D6 265/4885CYP2C19 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.